tiprankstipranks
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
US Market
KPTI
Karyopharm Therapeutics
RESEARCH TOOLSreports

Karyopharm Therapeutics (KPTI) Income Statement

1,226 Followers

Karyopharm Therapeutics Income Statement

Last quarter (Q4 2025), Karyopharm Therapeutics's total revenue was $34.08M, an increase of 11.58% from the same quarter last year. In Q4, Karyopharm Therapeutics's net income was $-102.20M. See Karyopharm Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 146.07M$ 145.24M$ 146.03M$ 157.07M$ 209.82M
Gross Profit
$ 140.12M$ 139.23M$ 141.09M$ 151.86M$ 206.42M
Operating Expenses
$ 230.82M$ 258.67M$ 270.63M$ 294.06M$ 304.69M
Depreciation and Amortization
$ 296.00K$ 340.00K$ 530.00K$ 621.00K$ 789.00K
EBITDA
$ -90.41M$ -38.60M$ -118.42M$ -139.31M$ -96.98M
Operating Income
$ -90.71M$ -119.44M$ -129.54M$ -142.20M$ -98.27M
Other Income/Expenses
$ -105.29M$ 43.08M$ -13.24M$ -22.72M$ -25.55M
Pretax Income
$ -196.00M$ -76.36M$ -142.78M$ -164.92M$ -123.82M
Net Income
$ -196.04M$ -76.42M$ -143.10M$ -165.29M$ -124.09M
Per Share Metrics
Basic EPS
$ -17.93$ -9.41$ -18.79$ -30.28$ -24.75
Diluted EPS
$ -17.93$ -9.41$ -18.79$ -30.28$ -24.75
Weighted Average Shares Outstanding
 10.94M 8.12M 7.61M 5.46M 5.01M
Weighted Average Shares Outstanding (Diluted)
 10.94M 8.12M 7.61M 5.46M 5.01M
Currency in USD

Karyopharm Therapeutics Earnings and Revenue History